Custom service

Antibody Purification Services

From crude supernatant or ascites to a formulation-ready batch.

Scale: 1 mg–10 g — per batchPurity: >95% — by SDS-PAGE and SECTimeline: 1–3 weeks — per batch

Purification is where the difference between a research reagent and a usable product is made. Hybridoma supernatant contains bovine IgG, transferrin and host cell protein; ascites contains lipids, host antibodies and proteases; a transient expression harvest contains DNA and endotoxin. Protein A captures the antibody but not the aggregates, the leached ligand or the endotoxin, and each of those has to be removed deliberately.

The standard sequence is capture, intermediate purification and polishing. Protein A or G affinity capture at neutral pH, elution at low pH with immediate neutralisation; ion exchange to separate charge variants and to remove aggregated species; and size exclusion where monomer content must be above 98%. Endotoxin removal is added when the batch is destined for in vivo work, using either a detergent wash on the affinity column or a dedicated removal resin.

We screen the purification sequence on a small aliquot before committing the batch. That trial identifies whether the antibody is stable at low pH — some are not, and require a milder elution or an alternative capture — and whether aggregates form during elution, which determines whether an ion exchange step is essential or optional.

Service Highlights

Where it fits

Purification services are used when a laboratory lacks the equipment or the scale, when a batch must meet a documented specification, and when a problematic sample — lipid-rich ascites, a low-titre supernatant, an antibody that aggregates on elution — needs process development rather than a kit.

It is not a way to rescue a low-titre source economically. If the supernatant contains 5 µg/mL, the cost per milligram of purified antibody will be high, and concentrating the culture or switching to a recombinant route is usually cheaper.

Documentation and QC

Every batch ships with a certificate of analysis: A280 concentration, SDS-PAGE under reducing and non-reducing conditions, SEC-HPLC chromatogram with monomer and aggregate percentages, isotype confirmation, endotoxin by LAL, and the buffer composition. Bulk batches include a retention sample held for twelve months.

Frequently asked questions

My antibody precipitates during low-pH elution. What now?

We test acid stability on a small aliquot before the batch, and where the antibody is labile we switch to a milder elution pH, add a stabiliser to the elution buffer, or use a non-protein A capture such as ion exchange or hydroxyapatite.

Can you remove bovine IgG from hybridoma supernatant?

Yes, but not with protein A alone, which binds bovine IgG as well. An ion exchange step or an anti-bovine IgG depletion step is added, and the residual level is measured by ELISA.

Do you offer sterile filling?

Filtration through 0.22 µm is standard. Filling into vials under aseptic conditions is available for batches intended for in vivo use, with sterility testing included.

Send a sample with its titre and intended use. We will run a trial purification and tell you the attainable purity and yield before committing the batch.

Service Highlights

  • Sequence designed per sample. Affinity capture, ion exchange and SEC combined according to the source material and the required purity.
  • Low-pH stability tested first. A trial elution on a small aliquot identifies acid-labile antibodies before the main batch is exposed.
  • Aggregate removal. SEC or preparative SEC-HPLC to bring monomer content above 98% where required.
  • Endotoxin control. Detergent wash, affinity-based removal or a dedicated resin, with LAL testing below 1 EU/mg.
  • Buffer formulation. PBS, histidine or Tris formulation at the concentration you specify, with optional glycerol or sucrose for stability.
  • Analytical package. A280, SDS-PAGE, SEC-HPLC, isotype, endotoxin and optional mass confirmation.

How the work runs

  1. Sample assessment

    Source, volume, titre and contaminants are reviewed. A small aliquot is purified as a trial to select the sequence and to test acid stability.

  2. Clarification

    Centrifugation and 0.45 µm filtration, with optional depth filtration for lipid-rich ascites or high-cell-density harvests.

  3. Affinity capture

    Protein A or G at neutral pH, wash with PBS and optionally with a detergent-containing buffer for endotoxin, elute at pH 3.0–3.5 and neutralise immediately.

  4. Intermediate purification

    Cation or anion exchange to remove aggregates, host protein and charge variants, with the gradient optimised on the trial run.

  5. Polishing

    SEC for aggregate removal and buffer exchange, or ultrafiltration/diafiltration for concentration into the final formulation.

  6. QC and release

    Purity, concentration, aggregation, endotoxin and identity, with a certificate of analysis for each batch.

Specifications & timeline

Scale
1 mg–10 g — per batch
Purity
>95% — by SDS-PAGE and SEC
Timeline
1–3 weeks — per batch
Starting material
Hybridoma supernatant, ascites, transient expression harvest, serum, egg yolk
Scale
1 mg to 10 g per batch
Purity
>95% by SDS-PAGE; monomer >98% by SEC where specified
Endotoxin
Below 1 EU/mg with dedicated removal steps
Formulation
PBS, histidine, Tris; concentration up to 50 mg/mL
Timeline
1–3 weeks per batch depending on scale and steps

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.